Preference for daily oral pills over long-acting antiretroviral therapy options among people with HIV.
Journal
AIDS (London, England)
ISSN: 1473-5571
Titre abrégé: AIDS
Pays: England
ID NLM: 8710219
Informations de publication
Date de publication:
01 08 2023
01 08 2023
Historique:
medline:
17
7
2023
pubmed:
8
6
2023
entrez:
8
6
2023
Statut:
ppublish
Résumé
To examine the characteristics of people with HIV (PWH) who prefer remaining on daily oral antiretroviral therapy (ART), rather than switching to long-acting ART (LA-ART). Building upon a discrete choice experiment (DCE), we examined characteristics of individuals who always selected their current daily oral tablet regimen over either of two hypothetical LA-ART options presented in a series of 17 choice tasks. We used LASSO to select sociodemographic, HIV-related, and other health-related predictors of preferring current therapy over LA-ART, and logistic regression to measure the associations with those characteristics. Among 700 PWH in Washington State and Atlanta, Georgia, 11% of participants ( n = 74) chose their current daily treatment over LA-ART in all DCE choice tasks. We found that people with lower educational attainment, good adherence, more aversion to injections, and who participated from Atlanta to be more likely to prefer their current daily regimen over LA-ART. Gaps in ART uptake and adherence remain, and emerging LA-ART treatments show promise to address these challenges and help a larger portion of PWH to achieve viral suppression, but preferences for these new treatments are understudied. Our results show that certain drawbacks of LA-ART may help to maintain demand for daily oral tablets, especially for PWH with certain characteristics. Some of these characteristics (lower educational attainment and Atlanta participation) were also associated with a lack of viral suppression. Future research should focus on overcoming barriers that impact preferences for LA-ART among those patients who could benefit most from this innovation.
Identifiants
pubmed: 37289570
doi: 10.1097/QAD.0000000000003620
pii: 00002030-202308010-00007
pmc: PMC10355802
mid: NIHMS1906358
doi:
Substances chimiques
Tablets
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
1545-1553Subventions
Organisme : NIAID NIH HHS
ID : P30 AI050409
Pays : United States
Organisme : NIMH NIH HHS
ID : R01 MH121424
Pays : United States
Organisme : NIAID NIH HHS
ID : P30 AI027757
Pays : United States
Organisme : NIA NIH HHS
ID : K01 AG071843
Pays : United States
Organisme : NIMH NIH HHS
ID : P30 MH123248
Pays : United States
Informations de copyright
Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc.
Références
UNAIDS. Understanding fast-track: accelerating action to end the AIDS epidemic by 2030. Geneva: UNAIDS; 2015.
Centers for Disease Control and Prevention. Monitoring selected national HIV prevention and care objectives by using HIV surveillance data United States and 6 dependent areas, 2020. Atlanta, GA: CDC; 2020.
Centers for Disease Control and Prevention. HIV basic statistics. Atlanta, GA: CDC; 2022.
Fauci AS, Redfield RR, Sigounas G, Weahkee MD, Giroir BP. Ending the HIV epidemic: a plan for the United States . JAMA 2019; 321:844–845.
Centers for Disease Control and Prevention. Ending the HIV epidemic in the U.S. Atlanta, GA: CDC; 2022.
Nance RM, Delaney JC, Simoni JM, Wilson IB, Mayer KH, Whitney BM, et al. HIV viral suppression trends over time among HIV-infected patients receiving care in the United States, 1997 to 2015: a cohort study . Ann Intern Med 2018; 169:376–384.
Katz IT, Ryu AE, Onuegbu AG, Psaros C, Weiser SD, Bangsberg DR, et al. Impact of HIV-related stigma on treatment adherence: systematic review and meta-synthesis . J Int AIDS Soc 2013; 16:18640.
Claborn KR, Meier E, Miller MB, Leffingwell TR. A systematic review of treatment fatigue among HIV-infected patients prescribed antiretroviral therapy . Psychol Health Med 2015; 20:255–265.
Simoni JM, Amico KR, Pearson CR, Malow R. Strategies for promoting adherence to antiretroviral therapy: a review of the literature . Curr Infect Dis Rep 2008; 10:515–521.
Brah AT, Barthold D, Hauber B, Collier AC, Ho RJ, Marconi VC, et al. The systematic development of attributes and levels for a discrete choice experiment of HIV patient preferences for long-acting antiretroviral therapies. Unpublished Research Square preprint. 2021. Available at: https://doi.org/10.21203/rs.3.rs-719332/v1 .
Barthold D, Brah AT, Graham SM, Simoni JM, Hauber B. Improvements to survey design from pilot testing a discrete-choice experiment of the preferences of persons living with HIV for long-acting antiretroviral therapies . Patient 2022; 15:511–520.
Olson AD, Meyer L, Prins M, Thiebaut R, Gurdasani D, Guiguet M, et al. An evaluation of HIV elite controller definitions within a large seroconverter cohort collaboration . PLoS One 2014; 9:e86719.
Bridges JF, Hauber AB, Marshall D, Lloyd A, Prosser LA, Regier DA, et al. Conjoint analysis applications in health—a checklist: a report of the ISPOR Good Research Practices for Conjoint Analysis Task Force . Value Health 2011; 14:403–413.
Harris PA, Taylor R, Minor BL, Elliott V, Fernandez M, O’Neal L, et al. The REDCap consortium: building an international community of software platform partners . J Biomed Inform 2019; 95:103208.
SurveyEngine GmbH. SurveyEngine. Berlin, Germany; 2021. Available at: www.surveyengine.com .
Tibshirani R. Regression shrinkage and selection via the LASSO . J Roy Stat Soc B (Methodol) 1996; 58:267–288.
Chen J, Chen Z. Extended Bayesian information criteria for model selection with large model spaces . Biometrika 2008; 95:759–771.
Bazargan M, Cobb S, Assari S. Discrimination and medical mistrust in a racially and ethnically diverse sample of California adults . Ann Fam Med 2021; 19:4–15.
Martin LT, Ruder T, Escarce JJ, Ghosh-Dastidar B, Sherman D, Elliott M, et al. Developing predictive models of health literacy . J Gen Intern Med 2009; 24:1211–1216.
Veldwijk J, Lambooij MS, de Bekker-Grob EW, Smit HA, de Wit GA. The effect of including an opt-out option in discrete choice experiments . PLoS One 2014; 9:e111805.
Sutphin J, DiSantostefano RL, Leach C, Hauber B, Mansfield C. Exploring decisional conflict with measures of numeracy and optimism in a stated preference survey . MDM Policy Pract 2021; 6:23814683211058663.
Scarsi KK, Swindells S. The promise of improved adherence with long-acting antiretroviral therapy: what are the data? . J Int Assoc Provid AIDS Care 2021; 20:23259582211009011.
Qazzaz H, Parganas C, Cory TJ. An evaluation of long-acting cabotegravir+ rilpivirine for the treatment of virologically suppressed adults living with HIV . Expert Opin Pharmacother 2022; 23:1485–1495.
Gupta SK, Berhe M, Crofoot G, Benson P, Ramgopal M, Sims J, et al. Lenacapavir administered every 26 weeks or daily in combination with oral daily antiretroviral therapy for initial treatment of HIV: a randomised, open-label, active-controlled, phase 2 trial . Lancet HIV 2023; 10:e15–e23.